When it comes to research, Pierre Fabre has always favored a partnership approach, as it believes that complementarity and sharing of expertise constitute innovation accelerators. Our historical partnership with the French National Center for Scientific Research (CNRS) in the development of vinorelbine (Navelbine®), the first cancer treatment marketed by the company in 1989, epitomizes this approach. For several years, this approach has been structured around partnerships with various French Public Research Institutions (CNRS, INSERM, CEA, etc.), as well as with innovative biotechnology companies (biotechs). This strategy of "open innovation" is intended to provide additional impetus and to accelerate our research and development activities.
Pierre Fabre has a long history of cooperation with the Centre national de la recherche scientifique (CNRS), French universities, and other public research bodies (INSERM, CEA). This cooperation is symbolic of the complementary approach to our respective knowledge: fundamental research for the CNRS, therapeutic research for Pierre Fabre. In January 2011, a four-year partnership agreement between the IRPF and CNRS was renewed for a third time. The mixed structure located on the Oncopole site aims to develop new drug candidates that act on the epigenetic regulation of the cancer process. (www.etac.cnrs.fr)
Pierre Fabre and the CNRS are also partners of the Banyuls-sur-Mer Oceanological Observatory located in Banyul-sur-Mer on the Mediterranean sea, as part of a mixed research team (CNRS, Pierre and Marie Curie University) that is dedicated to marine biotechnology research.
Our R&D teams also turn to other pharmaceutical companies that have technological, human and financial resources to lead Pierre Fabre’s molecules or monoclonal antibodies through their development process.
- In 2010, a licensing agreement was signed with AbbVie to develop a second monoclonal antibody, which is also extremely promising in oncology.
- In 2015, a collaboration with Array BioPharma Inc. is announced to globally develop and commercialize late-stage novel oncology products: binimetinib and encorafenib.